These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 33851014)

  • 1. A Case of SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Following Coronary Artery Bypass Surgery.
    Osafehinti DA; Okoli OJ; Karam JG
    AACE Clin Case Rep; 2021; 7(1):20-22. PubMed ID: 33851014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Euglycemic diabetic ketoacidosis following traumatic brain injury.
    Jang SW; Lee H
    Am J Emerg Med; 2024 Mar; 77():232.e1-232.e3. PubMed ID: 38216364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor-Related Euglycemic Diabetic Ketoacidosis: A Case Series.
    Meier M; Ansong B; Awobusuyi D; Lee-Oyagha R; Lopez S
    J Pharm Pract; 2024 Aug; ():8971900241273169. PubMed ID: 39123293
    [No Abstract]   [Full Text] [Related]  

  • 4. Case Report: Diabetic ketoacidosis after co-administration of empagliflozin and probenecid.
    Martin WP; Reidy N; Low J; Ahern T
    Wellcome Open Res; 2023; 8():268. PubMed ID: 39114818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights.
    Baek HS; Jeong C; Yang Y; Lee J; Lee J; Lee SH; Cho JH; Sohn TS; Son HS; Yoon KH; Lee EY
    Diabetes Metab J; 2024 Jun; ():. PubMed ID: 38853537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Significance of Precise Diabetes Diagnosis: A Case of Euglycemic Diabetic Ketoacidosis Induced by the Introduction of Empagliflozin with Simultaneous Reduction of Insulin Dosage.
    Bińczyk W; Dróżdż O; Siudek B; Głuszczyk AM; Plizga JI; Grajnert FJ
    Eur J Case Rep Intern Med; 2024; 11(6):004567. PubMed ID: 38846667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-surgical Euglycemic Diabetic Ketoacidosis in a Patient on Empagliflozin in the Intensive Care Unit.
    Bteich F; Daher G; Kapoor A; Charbek E; Kamel G
    Cureus; 2019 Apr; 11(4):e4496. PubMed ID: 31259114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative Euglycemic Ketoacidosis in Type 2 Diabetes Associated with Sodium-Glucose Cotransporter 2 Inhibitor: Insights Into Pathogenesis and Management Strategy.
    Chandrakumar HP; Chillumuntala S; Singh G; McFarlane SI
    Cureus; 2021 Jun; 13(6):e15533. PubMed ID: 34123681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond the Benefits: A Case Study on the Complications of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (Euglycemic Diabetic Ketoacidosis (DKA) and Takotsubo Cardiomyopathy).
    Sabanci R; Saaed M; Bandi A; Das K; Wilcox M
    Cureus; 2024 Feb; 16(2):e55068. PubMed ID: 38550506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-Glucose Cotransporter 2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: The Other Side of the Coin!
    Kamath SD; Kumar U; Shrivastava V
    Cureus; 2024 Apr; 16(4):e58341. PubMed ID: 38756291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case of Diabetic Ketoacidosis in a Patient on an SGLT2 Inhibitor and a Ketogenic Diet: A Critical Trio Not to Be Missed.
    Steinmetz-Wood S; Gilbert M; Menson K
    Case Rep Endocrinol; 2020; 2020():8832833. PubMed ID: 32855828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketoacidosis and SGLT2 Inhibitors: A Narrative Review.
    Morace C; Lorello G; Bellone F; Quartarone C; Ruggeri D; Giandalia A; Mandraffino G; Minutoli L; Squadrito G; Russo GT; Marini HR
    Metabolites; 2024 May; 14(5):. PubMed ID: 38786741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Euglycemic Diabetic Ketoacidosis With Acute Renal Failure: A Challenging Case for Clinicians.
    Rizwanullah ; Ahmadi T; Ahmad A; Khan W; Rosario-Curcio JC
    Cureus; 2024 May; 16(5):e60171. PubMed ID: 38872637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-Glucose Linked Transporter Inhibitors as a Cause of Euglycemic Diabetic Ketoacidosis on a Background of Starvation.
    Tauseef A; Asghar MS; Zafar M; Lateef N; Thirumalareddy J
    Cureus; 2020 Aug; 12(8):e10078. PubMed ID: 33005504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure among Patients with Type 1 Diabetes.
    Tecce N; de Alteriis G; de Alteriis G; Verde L; Tecce MF; Colao A; Muscogiuri G
    Healthcare (Basel); 2024 Mar; 12(7):. PubMed ID: 38610175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy.
    Papadokostaki E; Liberopoulos E
    Case Rep Endocrinol; 2019; 2019():3901741. PubMed ID: 31198610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor.
    Teng R; Kurian M; Close KL; Buse JB; Peters AL; Alexander CM
    Diabetes Spectr; 2021 Jan; 34(1):42-51. PubMed ID: 33627993
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2-inhibitor therapy.
    Westcott GP; Segal AR; Mitri J; Brown FM
    Endocrinol Diabetes Metab; 2020 Apr; 3(2):e00117. PubMed ID: 32318635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus.
    Ahmadieh H; Ghazal N; Azar ST
    Diabetes Metab Syndr Obes; 2017; 10():161-167. PubMed ID: 28496348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic ketoacidosis masked by both Euglycemia and a primary metabolic alkalosis.
    Hillock MF; Jarmon C; Metropulos AE; King R; Tchernodrinski S; Principe DR
    Oxf Med Case Reports; 2024 Jul; 2024(7):omae071. PubMed ID: 39006506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.